Reports Q3 revenue $15.362M, consensus $4.6M. “2024 has been a successful year for C4T marked by strong execution across our entire portfolio, which has continued to position us as a leader in targeted protein degradation science. We recently shared initial clinical data on CFT1946 demonstrating a well-tolerated safety profile and evidence of monotherapy anti-tumor activity in BRAF inhibitor exposed patients, and we delivered our second development candidate to Biogen,” said Andrew Hirsch, president and chief executive officer of C4 Therapeutics (CCCC). “We look forward to continuing this momentum with cemsidomide Phase 1 data in multiple myeloma and in non-Hodgkin’s lymphoma being presented at ASH, and multiple CFT1946 data readouts expected in 2025. Our continued focus on discovery research, clinical development and collaborations sets us up for an exciting future and for the potential to improve patients’ lives.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CCCC:
- C4 Therapeutics Appoints New Chief Scientific Officer
- C4 Therapeutics appoints Paige Mahaney, Ph.D., as Chief Scientific Officer
- C4 Therapeutics announces next steps for CFT1946
- C4 Therapeutics presents monotherapy data from CFT1946 Phase 1 trial
- C4 Therapeutics announces delivery of second development candidate to Biogen